| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/23/2004 | CN1507353A Compositions for use in treating IGE-associated disorders |
| 06/23/2004 | CN1507348A Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 06/23/2004 | CN1507347A Coated granules based on angiotensin-converting enzyme inhibitor |
| 06/23/2004 | CN1507344A Method to obtain microparticles containing a H*, K*-ATP enzyme inhibitor |
| 06/23/2004 | CN1507343A Method to obtain microparticle containing a H*, K*-ATP-enzyme inhibitor |
| 06/23/2004 | CN1506116A Process for preparing degradable polymer and medical composition containing the said polymer and use thereof |
| 06/23/2004 | CN1154510C Preparation of directly mouldable tabletting auxiliary |
| 06/23/2004 | CN1154508C Stimulation of host defence mechanisms against viral challenges |
| 06/23/2004 | CN1154507C Inhibition of binding of Hox and homeodomain containing proteins and uses thereof |
| 06/23/2004 | CN1154505C Use of gastrointstinal lipase inhibitors |
| 06/23/2004 | CN1154500C Process for preparing 1,3-oxygen-sulphur cyclopentane nucleotide like medicine composition |
| 06/23/2004 | CN1154496C Application of Odanpine of fluoxetine in medicine for treatment of refractory depression |
| 06/23/2004 | CN1154492C Medical composition containing pentosan polysulfate and its application |
| 06/22/2004 | US6753412 Human Eag2 |
| 06/22/2004 | US6753333 Arginine salt forms of s-(-)-9- fluoro-6,7-dihydro 8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,5h-benzo(i,j)quinolizine-2 -carboxylic acid, a process for their preparation and pharmaceutical formulations which are |
| 06/22/2004 | US6753325 Comprises vitamin d3 for controlling cell differentiation and/or cell proliferation |
| 06/22/2004 | US6753176 Genetic engineering; antiarthritic agents |
| 06/22/2004 | US6753150 Detection of modulators of advanced glycation end product activity; obtain sample containing advanced glycation end product activity, incubate with peptide monitor adjustment in activity, adjustment in activity indicates modulator |
| 06/22/2004 | US6753140 Nucleotide sequences coding preferential polypeptide for use in the treatment of diabetes and eating disorders |
| 06/22/2004 | US6753015 Microparticle compositions and methods for the manufacture thereof |
| 06/22/2004 | US6752102 Apparatus for producing a foam bovine teat dip |
| 06/22/2004 | CA2176926C .alpha.v.beta.3 integrin as a predictor of endometriosis |
| 06/22/2004 | CA2104793C Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen |
| 06/17/2004 | WO2004051222A2 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| 06/17/2004 | WO2004050894A2 Heart failure gene determination and therapeutic screening |
| 06/17/2004 | WO2004050615A2 Method of increasing neutrophil production using 2,3-benzodiazepines |
| 06/17/2004 | WO2004050121A1 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 06/17/2004 | WO2004050115A2 Combination treatment using exendin-4 and thiazolidinediones |
| 06/17/2004 | WO2004050110A1 Medicinal composition |
| 06/17/2004 | WO2004050097A1 Use of amphiphilic lipids for the preparation of a pharmaceutical composition for reducing tumor metastasis |
| 06/17/2004 | WO2004050096A2 Phosphoantigens for regulating an immune response |
| 06/17/2004 | WO2004050095A1 Use of a known substance for the treatment of cancer and bacterial and fungal infections |
| 06/17/2004 | WO2004050067A1 PHARMACEUTICAL FORMULATIONS COMPRISING β-2 ADRENORECEPTOR AGONISTS AND XANTHINES |
| 06/17/2004 | WO2004050059A1 Low viscosity liquid dosage forms |
| 06/17/2004 | WO2004050037A2 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 06/17/2004 | WO2004050033A2 Method of treating cancers |
| 06/17/2004 | WO2004050027A2 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | WO2004050020A2 Improved opioid pharmaceutical compositions |
| 06/17/2004 | WO2004050013A2 Material compositions and related systems and methods for treating cardiac conditions |
| 06/17/2004 | WO2004049904A2 Bioactive, resorbable scaffolds for tissue engineering |
| 06/17/2004 | WO2004039371A3 Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain |
| 06/17/2004 | WO2004039360B1 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004028470A3 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 06/17/2004 | WO2004028460A3 Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| 06/17/2004 | WO2004028456A3 Method and composition for treating neurodegenerative disorders |
| 06/17/2004 | WO2004016256A3 AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION |
| 06/17/2004 | WO2004010946A3 Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| 06/17/2004 | WO2004010941A3 Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
| 06/17/2004 | WO2004009023A3 Novel inhibitors of ubiquitin isopeptidases |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2003106660A3 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/17/2004 | WO2003105781A3 Ophthalmic compositions for treating ocular hypertension |
| 06/17/2004 | WO2003099110A3 Herbs and herbal combinations useful for the treatment of microbial infections |
| 06/17/2004 | WO2003097050A3 A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| 06/17/2004 | WO2003071281A3 Estrogen receptor interaction with a transcription factor |
| 06/17/2004 | WO2003059259A3 Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| 06/17/2004 | WO2003053997A3 Methods of increasing endogenous erythropoietin (epo) |
| 06/17/2004 | WO2003053334A3 Compositions and methods for the diagnosis and treatment of tumor |
| 06/17/2004 | WO2003051380A3 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 06/17/2004 | WO2003039341A3 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 |
| 06/17/2004 | WO2003037308A8 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 06/17/2004 | WO2003032810A3 Treatment and diagnosis of insulin resistant states |
| 06/17/2004 | WO2003028700A3 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 06/17/2004 | WO2003026564A9 Pharmaceutical compositions for the treatment of urinary disorders |
| 06/17/2004 | WO2003017992A3 Means for treatment of atherosclerosis |
| 06/17/2004 | WO2003015689A3 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 06/17/2004 | WO2003000018A3 Dopamine agonist formulations for enhanced central nervous system delivery |
| 06/17/2004 | WO2002086443A8 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| 06/17/2004 | US20040116699 Melanocortin receptor agonists |
| 06/17/2004 | US20040116672 Human sel-10 polypeptides and polynucleotides that encode them |
| 06/17/2004 | US20040116636 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 06/17/2004 | US20040116534 Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine |
| 06/17/2004 | US20040116533 Pharmaceutical composition |
| 06/17/2004 | US20040116529 Anticancer and chemopreventative agents and methods of use thereof |
| 06/17/2004 | US20040116516 Pharmaceutical composition |
| 06/17/2004 | US20040116514 Carotenoid compounds and vitamin E compounds; preventing progression of hepatic disease such as cirrhosis to hepatic cancer; lycopene, beta -carotene, alpha-carotene, other natural carotenoids, and alpha -tocopherol |
| 06/17/2004 | US20040116510 hydrochlorothiazide and/or losartan potassium with ezetimibe; preventing or reducing the risk for occurrence of an atherosclerotic disease event in a hypertensive patient |
| 06/17/2004 | US20040116509 Antiviral agent; reducing the activity of viral polymerase; 3-(4-Chloro-2,5-dimethyl-benzenesulfonylamino)-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid for example |
| 06/17/2004 | US20040116498 Regulations of lipids and/or bone density and compositions therefor |
| 06/17/2004 | US20040116497 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 06/17/2004 | US20040116483 Glucagon antagonists/inverse agonists |
| 06/17/2004 | US20040116460 Anticancer agents |
| 06/17/2004 | US20040116457 Agents for improving excretory potency of urinary bladder |
| 06/17/2004 | US20040116454 Pyrazole compounds useful as protein kinase inhibitors |
| 06/17/2004 | US20040116450 Antipruritics |
| 06/17/2004 | US20040116431 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 06/17/2004 | US20040116419 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 06/17/2004 | US20040116411 and at least one antiretroviral drug, such as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors |
| 06/17/2004 | US20040116407 therapy involving the use of pentamidine, or an analog of pentamidine, and chlorpromazine, or an analog of chlorpromazine |
| 06/17/2004 | US20040116405 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 06/17/2004 | US20040116400 Compounds, compositions, and methods |
| 06/17/2004 | US20040116395 Combinations for the treatment of inflammatory disorders |
| 06/17/2004 | US20040116388 triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides |
| 06/17/2004 | US20040116352 Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 |
| 06/17/2004 | US20040116346 For use in therapy of anemia, as well as in other functions associated with assays for EPO-R, studying EPO and EPO-R function, purification of EPO-R |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040116333 Administering to the individual a multimeric compound that binds to at least two P-Selectin Glycoprotein Ligand 1 (PSGL-1) proteins on the surface of a T cell to induces a signal transduction pathway that results in the death of the T cell |
| 06/17/2004 | US20040116327 Administering compound capable of simultaneously binding PPAR alpha and PPAR gamma or concomitantly administering a compound that selectively binds PPAR alpha with a compound that selectively binds PPAR gamma to prevent rupture |
| 06/17/2004 | US20040115772 Methods of inhibiting Helicobacter pylori |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |